SCHEMBL1577098

SCHEMBL1577098

Fc1ccc2c(nc(-c3ccccc3Br)n2CC2CCCCC2)c1F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.40
PTGER4 P35408 2/20 0.39
FBP1 P09467 5/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GNRHR P30968 1/20 0.35
ALOX5 P09917 2/20 0.34
BRD4 O60885 1/20 0.34
CYP1B1 Q16678 1/20 0.34
PRKACA P17612 1/20 0.34
RPS6KB1 P23443 1/20 0.34
GSK3B P49841 1/20 0.34
ROCK1 Q13464 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1577009 0.87 PTGER4 (0.40) PTGER4FBP1KDM4EALDH1A1NPSR1
SCHEMBL1577569 0.86 ALOX5 (0.43) GRM2PTGER4FBP1ALOX5BRD4
SCHEMBL1577603 0.84 LMNA (0.39) GRM2PTGER4FBP1KDM4ENPSR1
SCHEMBL1577199 0.82 NPSR1 (0.40) PTGER4FBP1KDM4EALDH1A1NPSR1
SCHEMBL1577478 0.82 FBP1 (0.38) PTGER4FBP1KDM4EALDH1A1NPSR1
SCHEMBL1482720 0.81 NR1H4 (0.43) GRM2PTGER4KDM4EALDH1A1NPSR1
SCHEMBL1577534 0.80 PTGER4 (0.43) PTGER4FBP1KDM4EALDH1A1
SCHEMBL1482899 0.79 PRKACA (0.53) GRM2KDM4EALDH1A1NPSR1HSD17B10
SCHEMBL1577077 0.79 CNR1 (0.39) PTGER4FBP1CNR2
SCHEMBL1577421 0.78 ALOX5 (0.43) PTGER4FBP1ALOX5BRD4CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed